Pharmaceuticals News

66.7% of participants achieved an antidepressant response by Day 2 following a single intranasal dose of BPL-003 in both the 10 mg (n=6) and 12 mg (n=6) cohortsDurable responses observed at Day 85:...

Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306...

Oslo, April 8, 2026: In connection with the Annual General Meeting of Zelluna ASA to be held on April 23, 2026, Anders Tuv, Chair of the Board of Directors, has, as of the date of this announcement,...

MELBOURNE, Australia and OXFORD, United Kingdom, April 08, 2026 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for...

Novonesis expands global footprint with acquisition of production facility in Southeast Asia Investment of around USD 50 million strengthens fermentation capabilities and supports the company’s...

Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients ~15,000 children are living with DMD in the U.S. NEW YORK, April 07, 2026 (GLOBE...

Puntos importantes: Diseñado para transformar las operaciones de ensayos clínicos para patrocinadores, centros de investigación y equipos de estudioLas soluciones basadas en perfiles de usuario e...

Sorotan: Dirancang untuk mentransformasi operasional uji klinis bagi sponsor, lokasi penelitian, dan tim studiSolusi berbasis persona dan berteknologi AI ini mengotomatiskan alur kerja serta...

Highlights: Entwickelt, um die Abläufe bei klinischen Studien für Sponsoren, Studienzentren und Studienteams zu optimierenPersonenorientierte, KI-gestützte Lösungen automatisieren Arbeitsabläufe und...

亮點優勢： 專為贊助商、研究中心及研究團隊而設，以革新臨床試驗的運作基於人物角色的人工智能推動解決方案，自動化工作流程並精簡監管，協助提升試驗速度、預測能力及質素基於 Fortrea 的旗艦平台 Xcellerate®，提供近乎實時的角色為本洞察分析 北卡羅來納州達勒姆, April 08, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE)...